At a glance
This entry retains the original phase 2 trial alongside the journal's expression of concern and the authors' later correspondence about adverse-effect under-reporting.
Identity & scope
Tesofensine is a small-molecule monoamine reuptake inhibitor, not a peptide. The selected trial studied an oral investigational medicine, not a catalogue vial or nasal product.
What the research shows
- The 2008 trial reported weight reductions with tesofensine plus dietary intervention, but subsequently received an expression of concern [1,2].
- The bibliographic record links the notice to correspondence titled Under-reporting of adverse effects of tesofensine [3]. The notice must travel with any citation of the original result.
Critical interpretation
Preserve the integrity notice with the efficacy citation
A trial can report an efficacy signal while its conduct or safety reporting remains in question. The journal expression of concern is therefore not a footnote to drop when reproducing a weight-loss headline. It is also not automatically a retraction: those publication statuses have different meanings. The linked correspondence specifically concerns adverse-effect under-reporting, but its full text was not retrieved here. Consequently this review does not reconstruct the inspection or assert that a particular corrected adverse-event count is known. Its interpretation stays within the verified publication trail. [1] [2] [3]
A later registry result adds context without resolving the earlier notice
The UMIN record prevents the mistaken impression that no later phase 3 study is documented anywhere. It lists a Mexican study, outcomes and participant flow, but the public disclosure occurred years after its stated study period. That timing limits the use of this registration to verify prospective outcome specification. Registry-entered results are useful primary evidence, yet they are not equivalent to independently appraising a complete journal report, protocol and dataset. They neither repair the separate historical trial nor establish long-term cardiovascular or psychiatric safety, and they do not validate catalogue nasal or vial preparations. [4] [2]
Limitations & uncertainties
- The notice and response have no PubMed abstracts; only their bibliographic records and linkage were verified here. Their full text requires further appraisal.
- A contested safety record, short follow-up and limited replication prevent a confident general safety conclusion. No catalogue-formulation equivalence was established.
Open research questions
- How do the complete inspection findings, corrected adverse-event data and subsequent independent trials affect the interpretation?
- Can longer-term cardiovascular and psychiatric outcomes be assessed with adequately reported controlled data?
Selected papers & source records
Download bibliography1. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial (opens in a new tab)
Astrup A, Madsbad S, Breum L, et al. (2008). The Lancet. DOI: 10.1016/S0140-6736(08)61525-1 (opens in a new tab) · PMID 18950853
- Design & population
- 24-week phase 2 randomized placebo-controlled trial in 203 adults receiving an energy-restricted diet.
- What the study found
- The paper reported additional weight reduction and increased heart rate in one active group. These results must be read with the subsequent expression of concern.
- Limits on interpretation
- Published expression of concern, PMID23561987. Do not treat the original adverse-event profile as complete or infer efficacy of a catalogue preparation.
2. Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial (opens in a new tab)
The Lancet, no named author listed in PubMed (2013). The Lancet. DOI: 10.1016/S0140-6736(13)60778-3 (opens in a new tab) · PMID 23561987
- Design & population
- Journal expression of concern linked to the 2008 obesity trial.
- What the study found
- PubMed explicitly classifies this notice as an Expression of Concern for PMID18950853.
- Limits on interpretation
- Bibliographic record verified, no abstract available. An expression of concern is not itself a retraction; the full notice was not reviewed here.
3. Under-reporting of adverse effects of tesofensine (opens in a new tab)
Astrup A, Madsbad S, Breum L, et al. (2013). The Lancet. DOI: 10.1016/S0140-6736(13)61563-9 (opens in a new tab) · PMID 23849924
- Design & population
- Authors' correspondence linked to the expression of concern.
- What the study found
- The primary record identifies a response specifically concerning adverse-effect under-reporting.
- Limits on interpretation
- No abstract available and full letter not reviewed. This bibliographic notice is not a new independent efficacy or safety trial.
4. Efficacy and safety of tesofensine for the treatment of obesity in adults: a phase 3 randomized controlled study (opens in a new tab)
Investigator-submitted UMIN-CTR record; principal investigator Reyes-Garcia JG (2024). UMIN Clinical Trials Registry.
- Design & population
- Registry results for a 24-week placebo-controlled Mexican study reporting 372 randomized participants.
- What the study found
- The registry reports larger average weight reductions in active groups than placebo and provides participant-flow and adverse-event summaries.
- Limits on interpretation
- Investigator-entered registry result, not a full peer-reviewed report appraised here. Disclosure in 2024 postdates the listed 2017-2018 study period. This does not resolve the separate 2008 trial notice.
Search & review scope
Targeted primary-record verification, with explicit follow-up of journal-integrity notices.. Checked 9 November 2026.
Original obesity trial, linked journal notices and an investigator-submitted Mexican phase 3 registry result, kept distinct from a peer-reviewed trial report.
Not a systematic review. Original trial abstract, notice metadata/linkage and public registry fields checked. The full integrity notices, any corrected dataset and a full publication of the registry study were not appraised.
Recorded search terms
- site.pubmed.ncbi.nlm.nih.gov/18950853 Tesofensine
- site.pubmed.ncbi.nlm.nih.gov tesofensine phase 3
- site.pubmed.ncbi.nlm.nih.gov/23561987 Expression of concern
- site.pubmed.ncbi.nlm.nih.gov/23849924 Under-reporting
- https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000061771
- site.thelancet.com 23561987 OR 60778-3
Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.
Cite this review
HeartPep. Tesofensine: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/us/research/library/tesofensine.
HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.
Buy from HeartPep.com
Laboratory research only. Not for human or veterinary use.